Culture system and method for in-vitro long-term maintenance of functions of mature hepatocytes and application
Through the culture system of BET and TEAD inhibitor combination, hepatocyte dedifferentiation and maintain hepatocyte function, solving the problem of maintaining liver cells in vitro function, realizing long-term function maintenance and redifferentiation of liver cells, and having important clinical application potential .
Patent Information
- Application Number
- CN202410844143.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-27
- Publication Date
- 2024-12-03
AI Technical Summary
In the prior art, it is difficult for hepatocytes to maintain proliferation and metabolic function in vitro, and are easy to dedifferentiate and age, which limits the clinical application of liver cell transplantation.
By using a combination of BET inhibitors and TEAD inhibitors, dedifferentiation of hepatocytes is inhibited, the expression of mature hepatocyte marker molecules such as ALB and HNF4A is maintained, and the dedifferentiated hepatocytes are induced. A specific culture system and method is used for a long time in vitro Maintain hepatocyte function.
It significantly inhibits the dedifferentiation of hepatocytes and maintains the expression of functional molecules of hepatocytes for more than 7 days, providing a solution to maintain long-term function of hepatocytes in vitro, and has important application potential for liver disease treatment and drug screening.
Smart Images

Figure CN119060937A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedical engineering, and relates to a culture system and method for maintaining the function of mature liver cells in vitro for a long time, and applications thereof. Background Art
[0002] Liver failure is a serious liver damage caused by acute or chronic factors, which can lead to serious disorders or decompensation of the liver's synthesis, metabolism, biotransformation and other functions. When liver failure enters the late stage, conventional internal and external surgical methods cannot effectively treat it. Currently, orthotopic liver transplantation (OLT) is the most effective means of treating late-stage liver failure. However, the shortage of donor livers has caused some patients to die while waiting for transplantation; and orthotopic liver transplantation also has limitations such as high cost, high incidence of complications, and the need for lifelong immunosuppressants.
[0003] Compared with in situ liver transplantation, hepatocyte transplantation has many potential advantages: 1. The operation is simpler, less invasive, and relatively low in cost; 2. Transplantation can be repeated as needed to maintain the efficacy; 3. Cells can be stored in a low-temperature environment for future use; 4. The patient's own liver is preserved; 5. The patient only needs 5%-15% of his own liver cells to achieve the treatment effect; 6. One donor liver source can match multiple patients, etc. However, there is also a problem of lack of sources for high-quality hepatocytes. In recent years, with the development of stem cell technology and cell reprogramming technology, a variety of cells have shown good potential for repairing damaged livers.
[0004] Primary hepatocytes (PHs) are effective cells for cell therapy of end-stage liver disease. Since the first case of hepatocyte transplantation to treat patients with cirrhosis was reported in 1992, there have been more than 100 reports of clinical applications of hepatocyte transplantation. One of the main bottlenecks in the clinical application of primary hepatocytes is that primary hepatocytes cannot maintain their proliferation capacity and metabolic function in vitro at the same time, and are prone to dedifferentiation and cell aging. In fact, even freshly isolated hepatocytes will lose the key functions of mature hepatocytes due to dedifferentiation when cultured in vitro for a short period of time. These shortcomings greatly limit the widespread application of hepatocyte transplantation in clinical practice. Developing functional liver cells in vitro is one possible solution. Summary of the invention
[0005] The present invention is conducted to solve the above-mentioned problems. In view of the problem in the prior art that it is difficult to maintain the function of hepatocytes after separation, a culture system and a culture method are provided for maintaining the function of mature hepatocytes in vitro for a long time by inhibiting the TEAdomain (TEAD) and Bromodomain and extraterminaldomain (BET) family protein signaling pathways, and an application thereof is also provided.
[0006] A first aspect of the present invention provides a culture system capable of maintaining the function of mature hepatocytes in vitro for a long period of time, comprising a basal culture medium and a culture factor used in combination with the basal culture medium.
[0007] Wherein, the culture factor is a BET inhibitor or a combination of a BET inhibitor and a TEAD inhibitor,
[0008] The concentration of the BET inhibitor is 0.001 to 10 μM, and the concentration of the TEAD inhibitor is 0.01 to 10 μM.
[0009] The use of this culture system can significantly inhibit the dedifferentiation of hepatocytes, especially the combination of the two inhibitors can better maintain the expression of hepatocyte functional molecules ALB and HNF4A; at the same time, the combination of the two inhibitors can induce the redifferentiation of dedifferentiated hepatocytes. This culture system can maintain the function of hepatocytes for a long time, and the expression level of mature hepatocyte marker molecules such as ALB and HNF4α can be maintained for more than 7 days.
[0010] Preferably, the composition of the basal medium and culture factors is as follows:
[0011] The basic culture medium includes a liquid basic culture medium, 0-5×B27 additives, 0-5×N2 additives, 1% penicillin / streptomycin, 0-100 mM nicotinamide, 0-1 mM dexamethasone, and 0-500 μg / mL vitamin C. In the formula, there is a combination of all added elements being 0. In order to avoid this situation, the minimum amount of each component is limited to 0.001.
[0012] BET inhibitors are selected from any one or more of BI894999, BAY1238097, ABBV-744, Birabresib, and Trotabresin;
[0013] The TEAD inhibitor is selected from any one or more of VT107, VT104, K975, and IAG939.
[0014] Further preferably, the basal culture medium is DMEM / F12 liquid basal culture medium;
[0015] The amount of B27 additive was 0.5×B27 additive, the amount of N2 additive was 0.5×N2 additive, the concentration of niacinamide was 2 mM, the concentration of dexamethasone was 10 mM, and the concentration of vitamin C was 60 μg / mL;
[0016] The concentration of the BET inhibitor is 0.001 to 5 μM (most preferably 2 μM), and the concentration of the TEAD inhibitor is 0.01 to 5 μM (most preferably 2 μM).
[0017] In a specific embodiment of the present invention, the above components are used for experiments, but each component is not limited to the above specific components. For example, among the BET inhibitors, 2 μM BI894999 is selected for experiments, but the other recorded BET inhibitors can also achieve the corresponding functions. The same is true for the selection of components of TEAD inhibitors.
[0018] The second aspect of the present invention provides a method for maintaining the function of mature hepatocytes in vitro for a long time using the above-mentioned culture system, comprising the following steps: after isolating primary hepatocytes, centrifuging the primary hepatocyte suspension to collect the cell precipitate, suspending it in a serum-free basal culture medium, and then evenly inoculating it in a Matrigel-coated culture dish, and adding the above-mentioned culture factors to the culture medium.
[0019] Preferably, the centrifugation conditions of the primary hepatocyte suspension are as follows: 50 g centrifugation twice, 5 minutes each time;
[0020] Primary hepatocytes are mature hepatocytes of mammals, such as primary mature hepatocytes of mice, rats or humans.
[0021] The culture results showed that the treatment with BET inhibitor and the combination of two types of inhibitors relatively maintained the expression of liver function genes Alb, Hnf4a, tyrosine aminotransferase (Tat) and Ttr; at the same time, it also inhibited the expression of liver progenitor cell-related molecules such as Afp and Ck19. Cell immunofluorescence staining further confirmed that the treatment with BET inhibitor and the combination of two types of inhibitors can significantly inhibit the dedifferentiation of hepatocytes, especially the inhibitor combination can better maintain the expression of hepatocyte function molecules ALB and HNF4A. It is confirmed that BET inhibitor and the combination of two types of inhibitors can maintain the function of mature hepatocytes in vitro.
[0022] The redifferentiation effect of inducing dedifferentiated hepatocytes was further verified. After primary hepatocytes were cultured in basal culture medium for one week and then the inhibitor combination was added, the expression of ALB and HNF4A were significantly upregulated, proving that the inhibitor combination can induce the redifferentiation of dedifferentiated hepatocytes.
[0023] Accordingly, the third aspect of the present invention provides the use of hepatocytes obtained by the culture method of the present invention in liver tissue engineering, liver failure treatment cells and in vitro drug screening for liver diseases. The research method of the present invention helps to obtain a new mechanism of in vitro hepatocyte functional dedifferentiation, a new way to maintain hepatocyte function in vitro, and the application potential of treating liver disease models.
[0024] The beneficial protection and effects of the present invention are as follows:
[0025] Through experiments, the research method of the present invention can maintain the function of mature hepatocytes in vitro for more than 7 days. The present invention shows that BET inhibitors and the combination of BET inhibitors and TEAD inhibitors can partially maintain the function of primary hepatocytes in vitro; and the inhibitor combination can induce the re-differentiation of dedifferentiated hepatocytes. The above results show that this study has important application potential and advantages in the treatment of liver diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 The results of the gene expression analysis experiment of V+B combination inhibiting hepatocyte dedifferentiation. The effects of small molecule inhibitors V, T and B and their combination on hepatocyte dedifferentiation were analyzed by quantitative PCR. Among them, the FH group was freshly isolated primary hepatocytes; the BM 1week group represented dedifferentiated hepatocytes cultured in hepatocyte basal medium for one week; V 1week, T 1week and B1week represented the addition of small molecule compounds VT107, T-5224 and BI894999 to the hepatocyte basal medium for one week, respectively; V+T 1week and V+B 1week represented the addition of small molecule compound combinations VT107+T-5224 and VT107+BI894999 to the hepatocyte basal medium for one week. AC shows the expression of YAP downstream genes Ctgf and Cyr61, and epithelial-mesenchymal transition marker gene Vimentin; DG shows the expression of hepatocyte function genes Alb, Hnf4a, Tat and Ttr; H and I show the expression of liver progenitor cell-related marker genes Afp and Ck19.
[0027] Figure 2 The results of immunofluorescence experiments showing that the V+B combination inhibited hepatocyte dedifferentiation. The BM 1week group represents primary hepatocytes cultured in hepatocyte basal medium for one week; V 1week, T 1week, and B1week represent hepatocyte basal medium supplemented with small molecule compounds VT107, T-5224, and BI894999 for one week, respectively; V+T 1week and V+B 1week represent hepatocyte basal medium supplemented with small molecule compound combinations VT107+T-5224 and VT107+BI894999 for one week.
[0028] Figure 3 The results of the gene expression analysis experiment of V+B combination promoting the redifferentiation of dedifferentiated hepatocytes. Among them, AH is the effect of the combination of small molecules BI894999 and VT107 on the expression of related genes of dedifferentiated hepatocytes detected by quantitative PCR. The BM 1week group represents primary hepatocytes cultured for one week using hepatocyte basal medium; the V+B 1week group represents primary hepatocytes cultured for one week with the addition of small molecule compound combination VT107+BI894999; the BM 2weeks group represents primary hepatocytes cultured for two weeks using hepatocyte basal medium; the BM 1week V+B 1week group represents primary hepatocytes cultured for one week using hepatocyte basal medium and then adding small molecule compound combination VT107+BI894999 and continuing to culture for one week; the FH group is newly isolated hepatocytes. A and B are the relative expressions of YAP downstream genes Ctgf and Cyr61; C and D are the relative expressions of liver progenitor cell-related marker genes Afp and Ck19; EH are the relative expressions of liver cell function genes Alb, Hnf4a, Tat and Ttr.
[0029] Figure 4 The results of immunofluorescence experiments showing that the V+B combination promoted the redifferentiation of dedifferentiated hepatocytes. Among them, AC is the immunofluorescence staining of ALB and HNF4A of hepatocytes after different treatments. BM 1week represents primary hepatocytes cultured in hepatocyte basal medium for one week; BM 2weeks represents primary hepatocytes cultured in hepatocyte basal medium for two weeks; BM 1weekV+B 1week group represents cells cultured in hepatocyte basal medium for one week and then added with VT107+BI894999 combination and continued to be cultured for one week. DETAILED DESCRIPTION
[0030] The present invention is now described in detail with reference to the embodiments, but the implementation of the present invention is not limited thereto.
[0031] The reagents and raw materials used in the present invention are all commercially available or can be prepared according to literature methods. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated by weight.
[0032] Example 1: Acquisition of primary hepatocytes
[0033] Hepatocytes from C57BL / 6 male mice (SLAC laboratory, Shanghai) were isolated by a two-step collagenase perfusion method: the liver was first rinsed with PBS, and then the liver was perfused with Hanks solution without calcium and magnesium ions, 1% BSA by mass volume, and 0.3% collagenase IV by mass volume (Thermo Fisher Scientific, Catalog #17104019); after the perfusion was completed, the mouse liver was cut into small pieces and placed in DMEM / F12 medium containing 0.3% collagenase IV (Thermo Fisher Scientific) and bathed at 37°C for 10 minutes. Afterwards, the primary hepatocyte suspension was centrifuged at 50g for 5 minutes, and the cell pellet was collected and suspended in serum-free DMEM / F12 medium.
[0034] Example 2: BET inhibitors can partially maintain primary hepatocyte function in vitro
[0035] Primary hepatocytes of C57BL / 6 male mice were isolated by the same method as in Example 1, and corresponding experiments and analyses were performed.
[0036] VT107 (V), T-5224 (T), BI894999 (B) and their combination were added to the basic medium (BM), and the hepatocytes were cultured for one week. The expression of genes related to hepatocyte function was detected by quantitative PCR. The results showed that both the B and V+B groups could significantly inhibit the expression of YAP downstream target genes Ctgf and Cyr61 ( Figure 1 A, 1B), while inhibiting the expression of vimentin, a marker gene for epithelial-mesenchymal transition ( Figure 1 C); Correspondingly, the treatment of B and V+B groups relatively maintained the expression of liver function genes Alb, Hnf4a, tyrosine aminotransferase (Tat) and Ttr ( Figure 1 D-1G); at the same time, the B and V+B groups also inhibited the expression of liver progenitor cell-related molecules such as Afp and Ck19 ( Figure 1 H, 1I).
[0037] Cell immunofluorescence staining further confirmed that B and V+B combination can significantly inhibit the dedifferentiation of hepatocytes, especially V+B combination can better maintain the expression of hepatocyte functional molecules ALB and HNF4A; while the effect of adding V or T alone is weak ( Figure 2 ). Quantitative analysis of the positive rates of ALB and HNF4A cells showed that the positive rates of liver cell functional molecules ALB and HNF4A cells under the V+B combination condition were 99.02±0.85% and 91.37±1.50%, respectively.
[0038] Example 3: Combination of BI894999 and VT107 can induce redifferentiation of dedifferentiated hepatocytes
[0039] Primary hepatocytes of C57BL / 6 mice were isolated by the same method as in Example 1, and corresponding experiments and analyses were performed.
[0040] Implementation Case 2 has demonstrated that the V+B combination can maintain the function of mature hepatocytes in vitro. This example further tests whether adding the V+B combination after hepatocytes dedifferentiate in vitro can induce hepatocyte redifferentiation.
[0041] First, the hepatocytes were cultured in basal culture conditions for one week to induce cell dedifferentiation, and then BI894999 and VT107 were added for another week. Quantitative PCR results showed that hepatocytes cultured in basal medium for one week (BM 1week) underwent significant dedifferentiation: YAP target genes Ctgf and Cyr61 were activated, liver progenitor cell markers Afp and Ck19 were upregulated, and hepatocyte functional genes (Alb, Hnf4a, Tat and Ttr) were downregulated ( Figure 3 ). This suggests that adding BI894999 and VT107 for another week (BM1weekV+B 1week) can reverse the dedifferentiation phenotype of hepatocytes and promote the redifferentiation of dedifferentiated hepatocytes.
[0042] Immunofluorescence staining was further used to verify the effect of V+B combination on promoting the redifferentiation of dedifferentiated hepatocytes. After one week of culture of primary hepatocytes in basal medium, the expression of ALB and HNF4A was significantly downregulated ( Figure 4 A), after two weeks of culture, only a few cells were positive for ALB and HNF4A ( Figure 4 B), primary hepatocytes were cultured in basal medium for one week, and then added with V+B combination, the expression of ALB and HNF4A were significantly upregulated ( Figure 4 C) demonstrates that the V+B combination can induce redifferentiation of dedifferentiated hepatocytes.
[0043] The above results show that the small molecule compound combination VT107+BI894999 can inhibit the YAP transcription complex, maintain hepatocyte function, and induce dedifferentiated primary hepatocytes to differentiate again.
[0044] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
Claims
1. A culture system for maintaining mature hepatocyte function in vitro for a long time, characterized in that: The method comprises a basal medium and a culture factor used in combination with the basal medium, The culture factor is a BET inhibitor or a combination of a BET inhibitor and a TEAD inhibitor, The concentration of the BET inhibitor is 0.001 to 10 μM, and the concentration of the TEAD inhibitor is 0.01 to 10 μM.
2. The in vitro culture system for maintaining mature hepatocyte function for a long term according to claim 1, characterized in that: in, The basic culture medium comprises a liquid basic culture medium, 0-5×B27 additive, 0-5×N2 additive, 1% penicillin / streptomycin, 0-100 mM niacinamide, 0-1 mM dexamethasone, and 0-500 μg / mL vitamin C; The BET inhibitor is selected from any one or more of BI894999, BAY1238097, ABBV-744, Birabresib, and Trotabresin; The TEAD inhibitor is selected from any one or more of VT107, VT104, K975, and IAG939.
3. The in vitro induction and long-term culture system of forebrain neural stem cells according to claim 2, characterized in that: in, The basal culture medium is DMEM / F12 liquid basal culture medium; The amount of B27 additive was 0.5×B27 additive, the amount of N2 additive was 0.5×N2 additive, the concentration of niacinamide was 2 mM, the concentration of dexamethasone was 10 mM, and the concentration of vitamin C was 60 μg / mL; The concentration of the BET inhibitor is 0.01 to 5 μM, and the concentration of the TEAD inhibitor is 0.01 to 5 μM.
4. The in vitro induction and long-term culture system of forebrain neural stem cells according to claim 2, characterized in that: in, The concentration of the BET inhibitor was 2 μM, and the concentration of the TEAD inhibitor was 2 μM.
5. A method for maintaining the function of mature hepatocytes in vitro for a long term using the culture system according to any one of claims 1 to 4, characterized in that: The method comprises the following steps: after primary hepatocytes are separated and obtained, the primary hepatocyte suspension is centrifuged to collect cell precipitates, which are suspended in a serum-free basic culture medium, and then evenly inoculated in a culture dish coated with Matrigel, and the culture factors are added to the culture medium.
6. The method according to claim 5, characterized in that: in, The centrifugation conditions of the primary hepatocyte suspension are as follows: centrifugation at 50 g for 2 times, 5 minutes each time.
7. The method according to claim 5, characterized in that: in, The primary hepatocytes are mature hepatocytes of mammals.
8. The method according to claim 5, characterized in that: in, The primary hepatocytes are primary mature hepatocytes of mice, rats or humans.
9. Use of the hepatocytes obtained according to the culture method of claim 5 in liver tissue engineering, liver failure therapeutic cells and in vitro drug screening for liver diseases.
